The 7 major alcohol-related disorders markets reached a value of USD 723.8 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,770.7 Million by 2035, exhibiting a growth rate (CAGR) of 8.47% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 723.8 Million |
Market Forecast in 2035
|
USD 1,770.7 Million |
Market Growth Rate 2025-2035
|
8.47% |
The alcohol-related disorders market has been comprehensively analyzed in IMARC's new report titled "Alcohol-Related Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Alcohol-related disorders encompass a range of conditions that are associated with excessive and problematic alcohol use. They can have significant negative impacts on various aspects of the patient's life, including their physical health, mental well-being, social functioning, etc. Some of the common symptoms are an inability to control or limit alcohol consumption, cravings or strong urges to drink, continued usage of alcohol despite adverse consequences, withdrawal signs when attempting to cut down or quit drinking, etc. Numerous other indications may involve neglecting personal and professional responsibilities, experiencing relationship problems and social isolation, engaging in risky behaviors while under the influence, suffering from physical health issues like liver damage or neurological impairments, etc. The diagnosis of alcohol-related disorders typically involves a comprehensive assessment that considers various factors, including the patient's drinking patterns, symptoms, and the impact of alcohol use on their physical and mental health, as well as their social functioning. Healthcare professionals may utilize diagnostic criteria, such as those outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), to evaluate if the patient meets the requirements for an alcohol-related disorder.
The increasing prevalence of various associated risk factors, such as depression, anxiety, bipolar disorder, adverse childhood experiences like abuse and neglect, social and peer influences, etc., is primarily driving the alcohol-related disorders market. In addition to this, the rising incidence of genetic variations in enzymes that are involved in alcohol metabolism, neurotransmitter systems, and reward pathways, which can influence how the body processes and responds to alcohol, is creating a positive outlook for the market. Moreover, the inflating application of various medications, such as naltrexone, acamprosate, disulfiram, etc., to reduce cravings, discourage alcohol consumption, and assist in maintaining sobriety is further bolstering the market growth. Apart from this, the escalating adoption of several behavioral therapies, including cognitive-behavioral therapy (CBT), that aid patients in identifying and modifying maladaptive thoughts and behaviors related to alcohol use is acting as another significant growth-inducing factor. Additionally, the emerging popularity of relapse prevention strategies, since they help to identify triggers, manage cravings, and develop healthy coping mechanisms to prevent relapse, is expected to drive the market during the alcohol-related disorders forecast period.
IMARC Group's new report provides an exhaustive analysis of the alcohol-related disorders market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for alcohol-related disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the alcohol-related disorders market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current alcohol-related disorders marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Vivitrol (Naltrexone controlled-release) | Alkermes |
Campral (Acamprosate calcium) | Forest Pharmaceuticals |
Sunobinop | Imbrium Therapeutics/Shionogi |
Psilocybin | Clairvoyant Therapeutics |
BPL-003 | Beckley Psytech Limited |
ASP8062 | Astellas Pharma |
CYB 003 | Cybin |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Alcohol-Related Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies